Cashu Research · House View · 16 November 2026
The market is paying up for comfort and dumping anything that needs patience. We think it has both wrong.
The ASX 200 looks calm. Underneath, the opportunities are anything but even. Our view: some familiar names carry valuations their earnings struggle to justify, while selected gold, copper, uranium and healthcare businesses offer more than their share prices suggest.
Here are five ASX stocks we'd own and five we'd avoid at the prices below. This is a house view, not a model portfolio, a short-selling recommendation or personal advice. “We'd own” describes our investment view, not an assertion that we hold the shares.
Prices and rounded market capitalisations are Cashu's research snapshot at the 13 November 2026 close, not live quotes. Company results and outlooks are dated below and linked in the sources. All share prices are Australian dollars unless stated otherwise. Charts default to the past 12 months and update separately.
We'd own: GMD · SFR · MC2 · PDN · TLXWe'd avoid: CBA · PME · DRO · BRN · BOE
The five ASX stocks we'd own
1. Genesis Minerals (ASX: GMD): buy the margin, not the gold-price mood
Reference close: A$7.05 · Market cap: about A$8.3bn
Gold has come off its highs. That does not mean every gold producer has lost its appeal. Genesis sold gold at A$6,175 an ounce in the June quarter; FY2027 all-in sustaining cost guidance is A$2,750–3,050 an ounce. Using that historical sale price against the guidance range implies roughly A$3,000 an ounce of operating headroom. It is not a forecast cash margin: gold prices, capital spending, tax and other costs still matter.
FY2026 EBITDA reached A$952m. At September's end, cash, bullion and liquid investments totalled A$598m, against A$200m of bank debt. September-quarter production of 72,107 ounces at A$2,966 an ounce kept the operating story on track.
The catalyst: the Vault Minerals merger. Management envisages a combined 600,000–700,000-ounce annual producer and about A$2bn of post-tax, undiscounted synergies over ten years. Those are management expectations, not money already earned or a present value. The combined strategic plan, targeted for the first half of 2027, is the next test.
What would change our mind: growth-project overruns, integration problems or another sharp fall in gold. FY2027 growth capital of A$380–420m leaves plenty to execute.
2. Sandfire Resources (ASX: SFR): strong copper, weaker shares
Reference close: A$19.48 · Market cap: about A$9.1bn
Copper does not need a new story. It needs miners that can deliver. Sandfire's FY2026 copper-equivalent production of 154,200 tonnes met annual guidance. Motheo in Botswana reached record annualised mill throughput of 7.1m tonnes in the June quarter, with copper-equivalent output up 65% on the preceding quarter.
The shares, meanwhile, have retreated from an August high of A$25 in Cashu's price snapshot. The September report recorded 38,900 tonnes of group copper-equivalent production, up 9% on the prior-year quarter but down 19% on the preceding quarter's restated 48,300 tonnes. Sandfire retained FY2027 guidance. We see a potential entry point, not a reason to ignore the operating risks.
The catalyst: more consistent delivery from the existing mines, with the Kalkaroo copper-gold project in South Australia adding longer-term development potential.
What would change our mind: recurring weather disruption or recovery problems at MATSA in Spain. A strong copper price cannot fix unreliable production.
3. Marimaca Copper (ASX: MC2): a project, not just a drill hole
Reference close: A$6.70 · Market cap: about A$910m
Marimaca has a completed feasibility study and environmental approval. Its November presentation outlines a 13-year mine life and 50,000-tonne annual steady-state copper production target, with US$587m of initial capital expenditure. The first ten years average 48,000 tonnes annually, including ramp-up. The headline US$2.09/lb all-in sustaining cost is a first-ten-year measure, not a whole-of-mine average.
The study's US$709m post-tax NPV, discounted at 8%, uses US$4.30/lb copper. At US$5.05/lb, management's sensitivity rises to about US$1.1bn. These are modelled project values, not equity values or share-price targets. Financing, dilution and execution still matter.
The catalyst: an acceptable financing package and a final investment decision. Marimaca's September accounts report US$135.5m of net working capital excluding current lease liabilities, including cash; that is not a cash balance and does not fund the full build. Pampa Medina adds exploration upside, not a free, fully valued asset.
What would change our mind: expensive debt, substantial dilution or a decision slipping into 2027. A permitted deposit still has to become a funded mine.
4. Paladin Energy (ASX: PDN): below the placement price, with work ahead
Reference close: A$7.17 · Market cap: about A$3.2bn before placement allotment
Paladin's A$525m equity raising at A$7.80 gives the company more funding and shareholders more dilution. At A$7.17, the stock is about 8% below the placement price. Buying below institutions is not a valuation method, but the reset makes the operating business worth another look.
Langer Heinrich, 75%-owned by Paladin, produced 4.82m pounds of uranium in FY2026. FY2027 guidance remains 5.1–5.6m pounds at US$44–48/lb. The September quarter's 1m pounds reflected a planned shutdown, with output weighted towards the second half.
The catalyst: delivery at Langer Heinrich while the raising supports Patterson Lake South and other commitments. The ASX placement comprises approximately 64m new shares, alongside about 3.3m shares in the Canadian placement. A further non-underwritten share purchase plan targets up to A$50m. The A$3.2bn reference market cap is before these new shares; dilution must be included when assessing value.
What would change our mind: another production miss. Patterson Lake South targets first production in 2031 and carries about US$1.23bn of pre-production capital. This raising does not eliminate future funding risk.
5. Telix Pharmaceuticals (ASX: TLX): commercial revenue, biotech risks
Reference close: A$13.62 · Market cap: about A$4.6bn
Telix is not a pre-revenue biotech. First-half 2026 revenue was US$477m, up 22%, while Precision Medicine segment adjusted EBITDA reached about US$132m. Full-year revenue guidance of US$950–970m gives investors a commercial business to assess alongside the development pipeline.
The catalyst: broader product sales following Pixclara's approval and first commercial doses in September, plus progress on the Zircaix resubmission. Telix's 21 October update explicitly includes anticipated Pixclara sales in guidance; it should not be counted again as wholly unmodelled upside. Approval, launch and commercial uptake are separate hurdles.
What would change our mind: another Zircaix setback, weaker core-product growth or adverse regulatory developments. Telix's H1 report disclosed an SEC subpoena concerning disclosures about prostate-cancer therapeutic candidates. It described a fact-finding request, cooperation, no charges asserted and no conclusions reached at that report date. We have not identified a subsequent public resolution in the sources reviewed. An inquiry is not a finding of wrongdoing. October's revised R&D guidance of US$240–260m also limits near-term profit.
The five ASX stocks we'd avoid
1. Commonwealth Bank (ASX: CBA): a premium needs earnings to match
Reference close: A$170.87 · Market cap: about A$286bn
CBA is a high-quality bank. That does not make it attractive at any price. The research puts it on about 25.7 times normalised earnings, versus 12.5 times for ANZ and 15.4 times for NAB. Different earnings definitions matter, but the premium is the point.
The first quarter of FY2027 delivered about A$2.8bn of cash profit, flat against the prior half's quarterly average, although up 8% on the prior-year quarter. Income and costs both grew 3% against that prior-half average; loan impairment expense was A$300m. The year-on-year growth matters, but we still want more behind a growth-stock multiple.
Why we'd avoid it: a large valuation premium leaves less room for ordinary banking results. Its index weight also makes that valuation relevant well beyond direct shareholders.
What would change our mind: a materially lower price or a credible route to sustained double-digit earnings growth.
2. Pro Medicus (ASX: PME): great software, demanding arithmetic
Reference close: A$202.57 · Market cap: about A$21.2bn
We are not arguing with Visage's product or hospital footprint. The forward contract book grew 41% to A$1.34bn. We are arguing with the price investors pay for that success.
Pro Medicus reported FY2026 net profit of A$265.3m against A$261.7m of revenue, reflecting items that should not simply be extrapolated. The company also reported underlying net profit of A$144.7m, up 24.1%: the core business is growing, not collapsing. The FY2027 consensus EPS estimate used here is A$1.95, implying roughly 104 times earnings at the reference share price. That estimate is not company guidance and can change. Today's valuation already asks a lot.
Why we'd avoid it: a big fall from the high does not automatically create value. Exceptional businesses can still deliver disappointing investment returns when bought too dearly.
What would change our mind: a substantial pullback or earnings and contract wins strong enough to justify the multiple.
3. DroneShield (ASX: DRO): demand is not the same as profit
Reference close: A$1.18 · Market cap: about A$1.1bn
Counter-drone demand is real. So is the cost of scaling. First-half revenue grew 74% to A$125.8m, but the statutory result swung to a A$32.2m loss and adjusted EBITDA to a A$12.4m loss. Orders need to convert into profitable delivery, not just bigger headlines.
Why we'd avoid it: operating losses sit alongside a regulatory overhang. In its 26 August results announcement, DroneShield said it continued to assist ASIC with an investigation into November 2025 ASX announcements and trading activity, and that any resulting action was unclear. Reporting dated 14 November 2026 describes the matter as continuing. An investigation is not a finding of wrongdoing, and we make no such finding.
What would change our mind: sales growth with costs controlled, plus clarity on the ASIC matter.
4. BrainChip (ASX: BRN): the technology still needs a paying business
Reference close: A$0.105 · Market cap: about A$240m
Interesting technology does not pay the bills by itself. BrainChip's June 2026 half delivered US$1.22m of revenue against a US$12m net loss. June cash was US$20.3m, with the company estimating roughly four quarters of funding at the then-current burn rate. That is a dated runway estimate, not a current cash balance.
Why we'd avoid it: commercial revenue remains small beside the spending required. Further funding could dilute existing shareholders, who already share the business across about 2.3bn shares.
What would change our mind: recurring licence and chip revenue that credibly covers cash burn. Until then, shareholders are paying for the wait.
5. Boss Energy (ASX: BOE): uranium exposure is not enough
Reference close: A$1.425 · Market cap: about A$590m
We like the uranium opportunity. We do not need to own every uranium mine. Boss published a new Honeymoon feasibility study on 27 August, setting out a revised production plan. FY2026 production of 1.41m pounds met revised guidance. Management says the new study supports continued economic production; our caution is about delivery against that plan, not a claim that the mine cannot work.
Why we'd avoid it: the investment case still needs evidence that the revised operating plan is reliable. A strong commodity price cannot substitute for a mine meeting its own production and cost targets.
What would change our mind: several quarters of delivery against the new plan. Paladin and Boss offer the same commodity exposure, but very different execution questions.
The common thread: price matters as much as the story
This is not a blanket bet on small caps or against large caps. It is a valuation and execution call. We prefer businesses where operating progress could improve the investment case over those where the share price already assumes too much.
The catalysts are specific: merger integration, mine delivery, project financing, product approvals and earnings. So are the reasons to change our minds. A cheap-looking multiple is a starting point, not a defence against being wrong.
Explore more Cashu research reports and investment ideas or the latest ASX market commentary.
Sources, disclosures and important information
Holdings: Cashu Group, the author, staff and related parties hold no positions, long or short, in any of the ten companies mentioned, as confirmed for this article.
Client relationships: none of the ten companies mentioned are current or recent Cashu clients, as confirmed for this article.
About this analysis: this article presents Cashu Research's house view, by Fox Slotemaker, as at 16 November 2026. Our views weigh each company's valuation, operating performance, catalysts and risks. “We'd own” and “we'd avoid” express our assessment at the stated prices, not a model portfolio or a promise of returns.
Data and estimates: reference prices and rounded market capitalisations are as at the 13 November 2026 close. Market data and broker estimates draw on Yahoo Finance, Morningstar, HotCopper and Listcorp; company results and outlooks are sourced below. Forecasts, synergies and project valuations are estimates, not guarantees. Non-IFRS measures, including underlying profit, EBITDA and AISC, may differ between companies. Currency, dilution and reporting periods affect comparisons. TradingView charts update separately from the article's dated figures.
Sources reviewed: company releases and filings below, accessed 16 November 2026. Regulatory descriptions are tied to the cited disclosure dates; neither an investigation nor a subpoena establishes wrongdoing. AI assistance was used in preparing and checking this article.
- Genesis: FY2026 results, September quarterly and 12 November AGM address on the Vault merger.
- Sandfire: June quarterly and September quarterly. September comparisons use that report's restated preceding-quarter figures.
- Marimaca: November presentation, DFS and cost assumptions and September financial statements.
- Paladin: September quarterly presentation and 13 November raising completion announcement.
- Telix: 21 October commercial and guidance update.
- CBA: 11 November Q1 FY2027 trading update.
- Pro Medicus: FY2026 results, reported and underlying profit.
- BrainChip: H1 2026 financial report.
- Boss Energy: FY2026 production announcement and 27 August results and new feasibility study presentation.
- Telix H1 2026 financial report, filed with the SEC.
- DroneShield H1 2026 results announcement, 26 August 2026.
- Switzer reporting on DroneShield, 14 November 2026. Secondary reporting, not a regulatory finding.
General advice warning: Cashu Research is a division of Cashu Group. Cashu Technologies Pty Ltd is a Corporate Authorised Representative (AR No. 001318029) of Adviser Solutions Group Pty Ltd (AFSL 485946). This article contains general financial product advice only and has been prepared without taking into account your objectives, financial situation or needs. Before acting, consider whether it is appropriate for you and seek independent advice. Past performance is not a reliable indicator of future performance. Views may change without notice. Small and mid-cap companies, explorers and developers carry a high level of risk. “Avoid” is not an instruction to short a security.